The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...

Or whatever” Sung to the tune of Victim C’s “Graduation (Friends ... It’s going to reach you.” Durham is home to one of the most shorted stocks. The semiconductor manufacturer Wolfspeed ...

From the Holderness Family to Grandma C, social media personalities around Raleigh and Durham explain what will get lost if ...

Numab Therapeutics announced a Series C extension to CHF 180 million, completing an oversubscribed CHF 50 million financing effort. Tune Therapeutics raised $175 million. Ouro Medicines launched with ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

Investors clearly appreciate the song Tune Therapeutics is singing, handing over $175 million in series B funds as the biotech takes its epigenetic silencing drug into the clinic. The funding has ...

The funding comes after the biotech company announced in November it was moving into the clinic with its lead drug, which is aimed at treating hepatitis B. Tune Therapeutics, which has dual ...

The Durham ID building in downtown Durham, NC holds the North Carolina office of Tune Therapeutics, a growing biotech startup moving into trials. Brian Gordon Launched from a Duke University lab ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...